JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Search

Integra LifeSciences Holdings Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

10.7 0.28

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

10.42

Max

10.86

Pagrindiniai rodikliai

By Trading Economics

Pajamos

3.7M

-1.7M

Pardavimai

33M

435M

Pelno marža

-0.392

Darbuotojai

4,427

EBITDA

12M

66M

Rekomendacijos

By TipRanks

Rekomendacijos

Parduoti

12 mėnesių prognozė

+2.9% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-46M

870M

Ankstesnė atidarymo kaina

10.42

Ankstesnė uždarymo kaina

10.7

Naujienos nuotaikos

By Acuity

50%

50%

157 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Integra LifeSciences Holdings Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-27 23:15; UTC

Svarbiausios naujienos

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026-04-27 23:08; UTC

Uždarbis
Pagrindinės rinkos jėgos

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026-04-27 23:48; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026-04-27 23:42; UTC

Rinkos pokalbiai

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026-04-27 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026-04-27 23:30; UTC

Rinkos pokalbiai

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026-04-27 23:08; UTC

Rinkos pokalbiai

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026-04-27 22:42; UTC

Rinkos pokalbiai

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026-04-27 22:10; UTC

Uždarbis

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026-04-27 21:56; UTC

Uždarbis

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026-04-27 21:44; UTC

Uždarbis

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026-04-27 21:43; UTC

Uždarbis

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026-04-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-27 20:39; UTC

Uždarbis

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Akcijų palyginimas

Kainos pokytis

Integra LifeSciences Holdings Corp Prognozė

Kainos tikslas

By TipRanks

2.9% į viršų

12 mėnesių prognozė

Vidutinis 11 USD  2.9%

Aukščiausias 12 USD

Žemiausias 9 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Integra LifeSciences Holdings Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Parduoti

6 ratings

0

Pirkti

4

Laikyti

2

Parduoti

Techninis įvertinimas

By Trading Central

12.75 / 16.41Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Rinkos nuotaikos

By Acuity

157 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Integra LifeSciences Holdings Corp

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services. It also sells instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute wounds; and surgical tissue repair products for hernia, tendon, peripheral nerve repair and protection. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
help-icon Live chat